In children and adolescents, OS and disease-free survival (DFS) after HSCT in bone marrow failure, MDS, or AML in patients with GATA2 deficiency were 65% and 51%, and those were comparable to the values in patients without GATA2 deficiency (81). Here, GATA2 is linked to Bone marrow hypocellularity.